BOSTON, Nov. 5 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. is pleased to announce that the Company has retained the services of Advertising Associates International to manage its 2010 marketing, promotional and advertising campaign. They offer complete media research, planning, placement and ad tracking analysis. They have been highly regarded in the marketing field for forty-five years and have represented numerous companies as they achieved their marketing goals.

The AAI team includes marketing, creative and technical specialists as well as consultants drawn from the medical, engineering and dental professions; people with experience in business development who have helped clients build partnerships to leverage their marketing and promotional budgets.

"We are pleased to be working with AAI once again to assist Solos Endoscopy gaining broader worldwide exposure. I was impressed with the results we achieved last time, and have high expectations for what our present marketing campaign will accomplish," stated Bob Segersten, President of Solos Endoscopy, Inc.

For more information on Advertising Associates International, visit: www.aai-agency.com

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare technology company whose mission is to develop and market breakthrough technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office with its catalog of FDA Approved products. Additional information is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Solos Endoscopy, Inc.

CONTACT: Brian Neff, Investor Relations of Big Apple Consulting USA for
Solos Endoscopy, Inc., +1-407-389-5900